FDA 483 - AGC Biologics A/S

An FDA inspection of AGC Biologics, Inc. in Copenhagen, Denmark, a drug substance manufacturer, revealed two significant observations. The firm failed to ensure adequate personnel training for sample handling operations, leading to high sample failure rates and impacted product quality. Additionally, the inspection noted a lack of timely implementation of change control for test method document updates, resulting in reoccurring deviations.